CDT Equity (CDT) Cash & Equivalents (2021 - 2026)
CDT Equity's (CDT) quarterly Cash & Equivalents came in at $97000.0 in Q1 2026, down 95.45% YoY from $2.1 million in Q1 2025, and down 93.57% on a QoQ basis from $1.5 million in Q4 2025.
CDT Equity (CDT) Cash & Equivalents (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Cash & Equivalents data on file, last reported at $97000.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 95.45% year-over-year to $97000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97000.0 (down 95.45% YoY) and the FY2025 annual result came in at $1.5 million, up 151.5% from the prior year.
- Cash & Equivalents slipped to $97000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $8.6 million in Q3 2023 to a low of $71000.0 in Q3 2024.
- A 5-year average of $1.7 million and a median of $837687.0 in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents sank 99.18% — and 2025, when it surged 5252.11%.
- Tracing CDT's Cash & Equivalents over 5 years: stood at $345777.0 in 2022, then surged by 1122.75% to $4.2 million in 2023, then plunged by 85.81% to $600000.0 in 2024, then surged by 151.5% to $1.5 million in 2025, then plunged by 93.57% to $97000.0 in 2026.
- The last three Cash & Equivalents figures came in at $97000.0 (Q1 2026), $1.5 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 747,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 747,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 3.33 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 219,000.00 |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 4.23 Mn |
| Sep 30, 2023 | 8.64 Mn |
| Jun 30, 2023 | 277,761.00 |
| Mar 31, 2023 | 90,606.00 |
| Dec 31, 2022 | 345,777.00 |
| Sep 30, 2022 | 728,072.00 |
| Jun 30, 2022 | 837,687.00 |
| Mar 31, 2022 | 964,602.00 |
| Dec 31, 2021 | 48,555.00 |